IVIG Dosing for HLH
The recommended dose of IVIG for hemophagocytic lymphohistiocytosis is up to 1.6 g/kg divided over 2-3 days 1.
Dosing Regimen
The 2019 Blood guidelines for adult HLH management provide the most authoritative dosing recommendation 1:
- Total dose: Up to 1.6 g/kg
- Administration: Split over 2-3 days
- This translates to approximately 0.5-0.8 g/kg per day when divided
Clinical Context and Evidence
When to Consider IVIG
IVIG may be added to standard HLH therapy based on its anti-inflammatory mechanisms 1:
- Inhibits complement activation
- Blocks antibody Fc fragments and macrophage Fc receptors
- Neutralizes cytokines
Specific Clinical Scenarios
HLH during chemotherapy: For patients with cytopenia prolonged after chemotherapy or persistent fever despite antibiotics, use corticosteroids (prednisolone 1-2 mg/kg or dexamethasone 5-10 mg/m²) combined with IVIG 1.6 g/kg over 2-3 days 1. Etoposide should be used sparingly in this setting to allow bone marrow recovery.
Less severe EBV-HLH: A conservative approach with short-course corticosteroids with or without IVIG is justified in patients with less severe disease or improving manifestations 1.
Supporting Research Evidence
Recent studies support IVIG efficacy in HLH:
- A 2024 pilot study used IVIG 1 g/kg for 5 days (total 5 g/kg) as part of a triplet regimen with ruxolitinib and high-dose corticosteroids, achieving 100% ICU survival 2
- A 2019 real-world study of 80 patients showed IVIG 2 g/kg total over 5 days combined with IV steroids achieved 76% remission and 82.5% survival at 6 months 3
- A 2024 systematic review of TB-associated HLH found IVIG significantly reduced mortality (p=0.04) 4
Important Caveats
Dosing Considerations
- The guideline states "up to" 1.6 g/kg, suggesting this is a maximum rather than mandatory dose 1
- Higher doses (2 g/kg total) have been used successfully in research settings 2, 3
- For patients at risk of renal dysfunction, thrombosis, or volume overload, use the minimum effective dose 5
Infusion Rate
When administering IVIG, start at 0.01 mL/kg/min (0.5 mg/kg/min) and increase gradually to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated 5. Monitor vital signs throughout infusion.
Role in Treatment Algorithm
IVIG is considered an adjunctive therapy, not first-line monotherapy 1. The backbone of HLH treatment remains:
- Corticosteroids (dexamethasone or methylprednisolone)
- Etoposide (for severe cases)
- IVIG as add-on therapy
Limitations
The guideline notes that IVIG use "has been questioned, at least in adult-onset Still's disease" 1, indicating the evidence base is not uniformly strong across all HLH triggers. However, the anti-inflammatory mechanisms provide biological plausibility for its use.